- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03683134
A Mediterranean Diet Nutrition Education Program for the Reduction of Cardiovascular Disease Risk in the Southeastern U.S. (HHP)
September 26, 2018 updated by: Michael W. Greene, Auburn University
A Pilot, Theory-Based, Nutrition Intervention Promoting a Mediterranean Diet for the Reduction of Cardiovascular Disease Risk Factors in a High-Risk Population of the Southeastern United States: The Healthy Hearts Program (HHP)
A 12-week, randomized nutrition intervention for the reduction of cardiovascular disease risk factors in a high-risk population in the southeastern United States.
The primary objective of this pilot study was to assess the efficacy of a Mediterranean diet intervention (education + extra-virgin olive oil (EVOO) and mixed nut supplementation) versus that of an American Heart Association (AHA) nutrition intervention (education) on serum blood lipid levels as markers for cardiovascular disease risk.
Researchers conducting this trial hypothesize that a greater reduction will be seen in cardiovascular disease risk factors in the Mediterranean diet intervention.
Study Overview
Status
Completed
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Auburn, Alabama, United States, 36849
- Auburn University Pharmaceutical Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Enrolled in Auburn University's health insurance program during the course of the study or a dependent of the enrollee during the course of the study
- BMI >24.9 (kg/m2)
- AND Meets two or more of the following
- Screening values classified in the "yellow" or "red" zone for:
- Systolic blood pressure (mmHg): Yellow zone: ≥140, Red zone: ≥160;
- Diastolic Blood pressure (mmHg): Yellow zone: ≥90, Red zone: ≥ 100;
- Fasting blood glucose (mm/dL): Yellow zone: ≥100, Red zone: ≥ 126
- Blood glucose (random) (mg/dL): Yellow zone: 140-200, Red zone > 200
- Total Cholesterol (mg/dL): Yellow zone: ≥200, red zone: ≥250
- Have a pre-existing diagnosis of hypertension, pre-diabetes, or hypercholesterolemia
- Current smoker (≥1 cigarette/day)
- Are: male (age: 55-80) or female (age: 60-80)
- A family history of premature coronary heart disease
- High risk ethnicity: Black, African American, American Indians/Alaska Natives, Non-Hispanic blacks, Mexican-Americans, Asian, Hispanic/Latino
Exclusion Criteria:
- Minors that are less than 19 years of age
- Individuals who are not enrolled in the Auburn University health insurance program for the 2016 plan year at baseline and have not yet completed initial visit
- Individuals who have not completed their 2015 "Healthy Tigers" biometric screening between January 1st and December 31st, 2015 (these can be completed by the "Healthy Tigers" staff or by submitting a healthcare provider form from the individuals' physician to the "Healthy Tigers" office), unless enrolled in "TigerMeds".
- Individuals who are pregnant or who intend to become pregnant during the 12-week health and wellness challenge.
- Individuals who anticipate absence or travel throughout the study that would interfere with their ability to complete the analysis at the mid-point and end of challenge.
- Patients with a peanut, tree nut, or olive oil food allergy or intolerance.
- Patients who are unable or unwilling to travel to Auburn University main campus for live health and wellness challenge events, individual assessments, personal appointments, and pre- and post- data collection
- Individuals who have NOT been stabilized on medication to treat or manage high blood pressure, high cholesterol, dyslipidemia, or pre diabetes for at least 12 weeks prior to the study.
- Patients who do not have access to the internet and therefore unable to complete the education portion of the study
- Individuals who have a pacemaker
- Patients who decline participation during informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mediterranean diet group
Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
|
Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet.
Seven education sessions will be delivered through an online platform.
Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks.
Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
|
Active Comparator: American Heart Association group
Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
|
Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health.
Seven education sessions will be delivered through an online platform.
Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic Blood Pressure Measurement
Time Frame: Change from at baseline blood pressure to 6-weeks
|
Measured in mmHg
|
Change from at baseline blood pressure to 6-weeks
|
Systolic Blood Pressure Measurement
Time Frame: Change from at baseline blood pressure to 12-weeks
|
Measured in mmHg
|
Change from at baseline blood pressure to 12-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diastolic Blood Pressure Measurement
Time Frame: Change from at baseline weight to 6-weeks
|
Measured in mmHg
|
Change from at baseline weight to 6-weeks
|
Change in Weight
Time Frame: Change from at baseline weight to 12-weeks
|
Measured in kilograms (kg)
|
Change from at baseline weight to 12-weeks
|
Calculation of Body Mass Index (BMI) (kg/m∧2)
Time Frame: Change from baseline weight to 6-weeks
|
Height in meters will be combined with weight in kilograms will be combined to report BMI in kg/m∧2)
|
Change from baseline weight to 6-weeks
|
Calculation of BMI (kg/m∧2)
Time Frame: Change from baseline weight to 12-weeks
|
Height in meters will be combined with weight in kilograms will be combined to report BMI in kg/m∧2)
|
Change from baseline weight to 12-weeks
|
Concentration of fasted total cholesterol
Time Frame: Change from baseline weight to 6-weeks
|
Measured in mg/dL
|
Change from baseline weight to 6-weeks
|
Concentration of fasted total cholesterol
Time Frame: Change from baseline weight to 12-weeks
|
Measured in mg/dL
|
Change from baseline weight to 12-weeks
|
Concentration of fasted high-density lipoprotein (HDL) cholesterol
Time Frame: Change from baseline weight to 6-weeks
|
Measured in mg/dL
|
Change from baseline weight to 6-weeks
|
Concentration of fasted high-density lipoprotein (HDL) cholesterol
Time Frame: Change from baseline weight to 12-weeks
|
Measured in mg/dL
|
Change from baseline weight to 12-weeks
|
Concentration of fasted low-density lipoprotein (LDL) cholesterol
Time Frame: Change from baseline weight to 12-weeks
|
Measured in mg/dL
|
Change from baseline weight to 12-weeks
|
Concentration of fasted low-density lipoprotein (LDL) cholesterol
Time Frame: Change from baseline weight to 6-weeks
|
Measured in mg/dL
|
Change from baseline weight to 6-weeks
|
Concentration of fasted triglycerides
Time Frame: Change from baseline weight to 6-weeks
|
Measured in mg/dL
|
Change from baseline weight to 6-weeks
|
Concentration of fasted triglycerides
Time Frame: Change from baseline weight to 12-weeks
|
Measured in mg/dL
|
Change from baseline weight to 12-weeks
|
A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio
Time Frame: Change from baseline weight to 12-weeks
|
Total cholesterol (mg/dL) will be used with HDL (mg/dL) to calculate total cholesterol to HDL ratio
|
Change from baseline weight to 12-weeks
|
A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio
Time Frame: Change from baseline weight to 6-weeks
|
Total cholesterol (mg/dL) will be used with HDL (mg/dL) to calculate total cholesterol to HDL ratio
|
Change from baseline weight to 6-weeks
|
Concentration of fasted blood glucose
Time Frame: Change from baseline weight to 6-weeks
|
Measured in mg/dL
|
Change from baseline weight to 6-weeks
|
Concentration of fasted blood glucose
Time Frame: Change from baseline weight to 12-weeks
|
Measured in mg/dL
|
Change from baseline weight to 12-weeks
|
A calculation of waist (inches) to height (inches) ratio
Time Frame: Change from baseline weight to 12-weeks
|
Waist circumference in inches will be calculated with height measurement in inches to report the waist-to-height ratio
|
Change from baseline weight to 12-weeks
|
A calculation of waist (inches) to height (inches) ratio
Time Frame: Change from baseline weight to 6-weeks
|
Waist circumference in inches will be calculated with height measurement in inches to report the waist-to-height ratio
|
Change from baseline weight to 6-weeks
|
Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin
Time Frame: Change from baseline weight to 6-weeks
|
Fasting plasma glucose in mg/dL and fasting serum insulin in milliUnits (mU)/I will be used to calculate HOMA-IR as an indicator for insulin resistance.
|
Change from baseline weight to 6-weeks
|
Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin
Time Frame: Change from baseline weight to 12-weeks
|
Fasting plasma glucose in mg/dL and fasting serum insulin in mU/I will be used to calculate HOMA-IR as an indicator for insulin resistance.
|
Change from baseline weight to 12-weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Michael W Greene, PhD, Auburn University
- Principal Investigator: Amy W Willis, MS, RD, Auburn University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 23, 2017
Primary Completion (Actual)
September 7, 2017
Study Completion (Actual)
September 7, 2017
Study Registration Dates
First Submitted
September 20, 2018
First Submitted That Met QC Criteria
September 21, 2018
First Posted (Actual)
September 25, 2018
Study Record Updates
Last Update Posted (Actual)
September 27, 2018
Last Update Submitted That Met QC Criteria
September 26, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- The Healthy Hearts Program
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Mediterranean diet
-
Purdue UniversityMushroom CouncilCompleted
-
University of East AngliaNewcastle UniversityRecruitingDepression, AnxietyUnited Kingdom
-
University of California, IrvineCompletedPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Disorder | Myeloproliferative SyndromeUnited States
-
Gangnam Severance HospitalUnknown
-
Federico II UniversityCompletedMediterranean Diet | Neuroendocrine Tumours (NETs)Italy
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
University of California, DavisCompletedInflammation | Diet Modification | HDLUnited States
-
michal rollUnknown
-
University of Campania "Luigi Vanvitelli"CompletedType 2 Diabetes MellitusItaly
-
Chih-Ping ChungNational Yang Ming Chiao Tung UniversityRecruiting